secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-04-24T23:59:59+00:00
Accession:  0001641172-25-005946
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma CEO letter updates ENV105 trials, DoD grant, and analyst coverage
-------------------------------------------------------------------------------

- ENV105 in Phase 2 prostate cancer and Phase 1 lung cancer trials; interim efficacy data expected end of Q2 2025.
- CSO lab received $876k DoD grant for biomarker study; trial sites expanded to University of Utah and City of Hope.
- Developing KROS101 GITR ligand agonist; data presented at AACR, SITC, and upcoming ASCO.
- Non-dilutive government grants received; robust IP portfolio; analyst coverage from EF Hutton, Maxim, HC Wainwright, and others.
- Financially strong due to recent private placement and non-dilutive funding; attending D. Boral and HC Wainwright conferences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000164117225005946/0001641172-25-005946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000164117225005946/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-005946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer